London’s stock exchange is sick. Years of outperformance by those across the Atlantic have left its leading shares on ratings far below those of comparative businesses elsewhere. Volumes traded are a fraction of what they once were, while not enough companies are coming to the market to balance the losses by takeovers or failures. So: sick, nigh unto death, or a wonderful buying opportunity?